| Stage | CBT | % of rev | CNMD | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $982M | 100.00% | $336M | 100.00% | CBT ×2.93 |
| Gross profit | $184M | 18.74% | $189M | 56.37% | CNMD +37.6pp |
| Operating income | $98M | 9.98% | $37M | 11.07% | CNMD +1.1pp |
| Pre-tax income | $58M | 5.91% | $26M | 7.75% | CNMD +1.8pp |
| Net income | $14M | 1.43% | $20M | 5.90% | CNMD +4.5pp |
| Stage | CBT | CNMD | Gap · A − B |
|---|---|---|---|
| Revenue | $982M100.00% | $336M100.00% | CBT ×2.93 |
| Gross profit | 18.74%$184M | 56.37%$189M | CNMD +37.6pp |
| Operating income | 9.98%$98M | 11.07%$37M | CNMD +1.1pp |
| Pre-tax income | 5.91%$58M | 7.75%$26M | CNMD +1.8pp |
| Net income |
| 1.43%$14M |
| 5.90%$20M |
| CNMD +4.5pp |
None
No disclosed counterparties: CBT.